L & S Advisors Inc decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 8.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,372 shares of the company’s stock after selling 5,686 shares during the quarter. L & S Advisors Inc’s holdings in Zoetis were worth $4,041,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in ZTS. Northwestern Mutual Wealth Management Co. increased its stake in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Harfst & Associates Inc. grew its stake in shares of Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after purchasing an additional 260 shares during the period. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after purchasing an additional 1,360 shares during the period. Almanack Investment Partners LLC. acquired a new position in shares of Zoetis during the 2nd quarter worth $119,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zoetis during the 2nd quarter worth $140,000. Hedge funds and other institutional investors own 93.33% of the company’s stock.
ZTS has been the topic of a number of recent analyst reports. BMO Capital Markets set a $65.00 price target on shares of Zoetis and gave the stock a “hold” rating in a research note on Wednesday, October 25th. BidaskClub raised shares of Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 price target on shares of Zoetis in a research note on Tuesday, October 24th. Morgan Stanley raised shares of Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price target on the stock in a research note on Wednesday, November 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $65.00 price target on shares of Zoetis in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Zoetis has an average rating of “Buy” and an average target price of $68.24.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The firm’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 EPS. equities analysts predict that Zoetis Inc. will post 2.37 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Thursday, November 9th were issued a $0.105 dividend. The ex-dividend date was Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a yield of 0.59%. Zoetis’s dividend payout ratio (DPR) is 22.11%.
COPYRIGHT VIOLATION NOTICE: “L & S Advisors Inc Trims Position in Zoetis Inc. (ZTS)” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/12/07/l-s-advisors-inc-trims-position-in-zoetis-inc-zts.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.